Health experts on Monday began a probe of how the WHO responded to the H1N1 (swine flu) pandemic “nearly a year after global alarm was raised over the new swine flu strain,” Agence France-Presse reports (Capella, 4/12).
Crucell, the Dutch biotechnology company, “said on Tuesday it had agreed with Britain’s GlaxoSmithKline [GSK] to jointly develop a malaria vaccine candidate, without disclosing financial details,” Reuters reports (Gray-Block, 4/6).
Also In Global Health News: Iraq’s Health System; HIV Travel Restrictions; India Cholera Vaccine; HIV/AIDS Prevention In Indonesia; U.S. Federal Quarantine Regulations
IRIN Examines ‘Long And Complicated’ Process To Developing Iraq’s Health System IRIN examines how decades of conflict in Iraq have stymied development of the country’s health system. The piece includes comments by Iraqi Health Minister Salih al-Hasnawi, who describes the process of “developing [the country's health facilities] to reach international…
Although H1N1 (swine flu) “has waned across much of the United States, the southeast is reporting an increase in cases of the H1N1 virus, U.S. health officials said on Monday,” Reuters reports. During a conference call with reporters, Anne Schuchat of the CDC reported an uptick in the number of H1N1 cases reported in Alabama, South Carolina and Georgia (Allen, 3/29).
Also In Global Health News: H1N1; USAID’s Global Pulse; Rotavirus Vaccine; Uzbek Doctors; Zimbabwe Development; Malaria Vaccine
Independent Committee Formed To Evaluate WHO’s Response To H1N1; Cuba To Offer H1N1 Vaccine To 1.1 M WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to…
The GAVI Alliance and the Global Fund to Fight AIDS, Tuberculosis and Malaria “on Friday began an effort to raise as much as $24 billion from members of the Group of 20 nations that will test whether a major push begun a decade ago against infectious diseases can survive the global recession,” the Wall Street Journal reports. The two groups held meetings last week in The Hague with government representatives from existing and potential donor nations, according to the newspaper.
GlaxoSmithKline, Pfizer Will Supply 600M Doses Of Reduced-Price Pneumococcal Vaccines To Developing Countries Over 10 Years, GAVI Says
The GAVI Alliance on Tuesday formally announced that drugmakers GlaxoSmithKline and Pfizer had signed off on a “10-year deal â€¦ to supply 60 million doses a year of cut-price pneumococcal vaccines to developing nations,” Reuters reports. The agreement is under what’s “called an Advance Market Commitment (AMC) which guarantees a market for vaccines supplied to poor nations but sets a maximum price drugmakers can expect to receive,” the news service writes (Kelland, 3/23).
The WHO on Monday advised developing countries to continue administering GlaxoSmithKline’s Rotarix vaccine â€“ which offers protection to children against the diarrhea-causing rotavirus â€“ after the FDA advised doctors in the U.S. to temporarily stop using the vaccine following the discovery it was “contaminated with an apparently harmless pig virus,” Reuters reports. “Rotavirus is the leading cause of severe childhood diarrhea and causes more than 500,000 deaths from dehydration among young children worldwide, mostly in countries where vaccination isn’t common,” the Wall Street Journal writes (Corbett Dooren/Favole, 3/23).
The WHO on Friday announced “it had delivered the first doses of H1N1 [swine flu] vaccine to Cuba, and a dozen countries in Africa would receive millions of doses in coming weeks,” Reuters reports. According to WHO spokeswoman Karen Mah, Cuba received an estimated 1.1 million doses Wednesday, and Honduras and El Salvador shipments are “en route,” according to the news service.
Lancet Study Finds Level Of HIV Services For IDUs ‘Is Poor In Many Countries’ A Lancet studyÂ performed a systematic review ofÂ HIV prevention and treatment services targeting injecting drug users (IDUs) globallyÂ basedÂ on the availability of “core interventions for IDUs: needle and syringe programmes (NSPs), opioid substitution therapy (OST) and other drug…